IELSG49 | Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL) |
Participants required: | 24 |
Investigator responsible(s): | A. Stathis, D. Rossi, E. Zucca |
Objective(s): | The primary objective of the IELSG49 trial is to determine the efficacy of tafasitamab in combination with acalabrutinib in patients with relapsed or refractory MZL. |